3-Hydroxybutyric acid
|
Basic information |
| Metabolite name | 3-Hydroxybutyric acid |
 | HMDB0000357 |
 |
C01089 |
 |
441 |
| Synonyms | beta-hydroxybutyrate; |
| No. of studies | 36 |
|
Basic information |
| Metabolite name | 3-Hydroxybutyric acid |
| HMDB0000357 |
|
C01089 |
|
441 |
| Synonyms | beta-hydroxybutyrate; |
| No. of studies | 36 |
|
Relationship between 3-Hydroxybutyric acid and depression (count: 36) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type4 | remitted group vs. non-remitted group | Plasma | Human | Up |
| Study M017 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M058 | Type1 | depressed HBV-infected patients group vs. control group and non-depressed HBV-infected group | Urine | Human | Up |
| Study M062 | Type1 | CUMS group vs. control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Down |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M1071 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Prefrontal cortex | Cynomolgus monkey | Up |
| Study M1140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M610 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M625 | Type1 | depression group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M739 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M894 | Type1 | electromagnetic field exposure group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M947 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M947 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |